Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price boosted by investment analysts at JPMorgan Chase & Co. from $24.00 to $25.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 25.74% from the company’s previous close.

Several other brokerages also recently issued reports on AMRX. Leerink Partners assumed coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price target for the company. Oppenheimer initiated coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 price objective on the stock. Weiss Ratings upgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Zacks Research raised Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. Finally, Barclays boosted their price target on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 17th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX traded down $0.33 during trading hours on Wednesday, hitting $19.88. 2,047,642 shares of the stock were exchanged, compared to its average volume of 2,410,447. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The company has a market cap of $6.35 billion, a PE ratio of 40.47, a price-to-earnings-growth ratio of 2.38 and a beta of 1.24. The company’s fifty day simple moving average is $19.22 and its two-hundred day simple moving average is $15.82. Amneal Pharmaceuticals has a 1-year low of $11.14 and a 1-year high of $21.68.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.03. The firm had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. On average, sell-side analysts predict that Amneal Pharmaceuticals will post 0.95 EPS for the current year.

Insider Buying and Selling

In related news, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the transaction, the director directly owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 over the last 90 days. 17.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AMRX. Allspring Global Investments Holdings LLC boosted its stake in Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after acquiring an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Amneal Pharmaceuticals during the 2nd quarter worth approximately $17,573,000. Principal Financial Group Inc. increased its holdings in Amneal Pharmaceuticals by 527.9% during the 1st quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock valued at $12,089,000 after purchasing an additional 817,652 shares during the period. Congress Asset Management Co. lifted its stake in shares of Amneal Pharmaceuticals by 94.7% in the 3rd quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock valued at $30,701,000 after purchasing an additional 741,577 shares during the period. Finally, Quartz Partners LLC bought a new position in Amneal Pharmaceuticals in the 1st quarter worth about $5,559,000. 31.82% of the stock is owned by institutional investors.

Key Stories Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue was approximately $863 million, while adjusted diluted EPS of $0.26 beat analyst expectations. Adjusted EBITDA was $207 million. Amneal Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Amneal raised its 2026 full-year guidance, citing growth in its Affordable Medicines and Specialty businesses. The improved outlook may support expectations for continued growth. AMRX Q3 Earnings & Sales Beat Estimates, FY’26 Guidance Raised
• Negative Sentiment: The company recorded a GAAP net loss of $22 million, or $0.06 per diluted share, and disclosed asset impairment charges. These items may weigh on sentiment despite the adjusted earnings beat. Amneal Announces Asset Impairment Charges

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.